StockDuty ← Dashboard Aug 17, 2026 01:34 PM ET
CatalystFDA/Bio

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

Phase 3 trial progress and Q2 earnings beat drove investor sentiment.

What changed
Why it matters
Phase 3 trial progress and Q2 earnings beat drove investor sentiment.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →